Diatec Monoclonals AS, the leading Norwegian producer of monoclonals antibodies, joins forces with Curida to further increase growth and development opportunities.
Diatec is a Norwegian biotechnology company with more than 25 years experience in antibody production and conjugation. “Diatec has 35 highly competent employees and has R&D and manufacturing facilities in Oslo. Through the acquisition of Diatec we add a highly competent team and new capabilities in modern biological production of pharmaceuticals. Biological manufacturing processes are behind many of the recent advances in pharmaceuticals and vaccines, and the growth potential is enormous”, says Curida CEO, Leif Rune Skymoen. Curida is a Contract Development and Manufacturing Organization (CDMO) for pharmaceuticals based in Norway. Curida was established in 2015 through an employee and management buyout of the former Takeda Nycomed site in Elverum. Curida is owned by management and employees along with Norwegian investors Canica, Stokke Industri and Klaveness Marine, as well the governmental investment fund Investinor.
Alpha Corporate Finance advised Diatec Monoclonals and its shareholders in the sale to Curida.
Alpha Corporate Finance
Advised in the sale of
Diatec Monoclonals AS
to